Can Pfizer Seize Share in This Multibillion-Dollar Market?

Submitted by admin on August 12, 2021 - 12:09am

Source:

Motley Fool

News Tags:

Headline:

snippet:

JAK inhibitors are man-made small-molecule drugs that regulate overactive immune systems to help prevent them from attacking the body.
Pfizer's JAK inhibitor ritlecitinib delivered promising phase 2b/3 results in its study of an autoimmune disease that results in hair loss.
If the pause on regulatory approval of JAK inhibitors is eventually lifted, ritlecitinib could be a huge beneficiary.

Search form